Other
AOCI - Cash Flow Hedge Reclassification (Next 12 Months)
AbbVie AOCI - Cash Flow Hedge Reclassification (Next 12 Months) decreased by 350.0% to -$36.00M in Q3 2025 compared to the prior quarter.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryProfitability
SignalContext dependent
VolatilityModerate
First reportedQ3 2018
Last reportedQ3 2025
How to read this metric
Provides visibility into future earnings volatility related to existing hedge contracts.
Detailed definition
This represents the portion of gains or losses on cash flow hedges currently held in Accumulated Other Comprehensive Inc...
Peer comparison
Standard disclosure for companies using hedge accounting under ASC 815.
Metric ID:
aoci_cash_flow_hedge_reclassification_12mHistorical Data
3 periods
| Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|
| Value | $105.00M | -$8.00M | -$36.00M |
| QoQ Change | — | -107.6% | -350.0% |
Range-$36.00M – $105.00M
Current Streak2+ quarters decline
AOCI - Cash Flow Hedge Reclassification (Next 12 Months) at Other Companies
Frequently Asked Questions
- What is AbbVie's aoci - cash flow hedge reclassification (next 12 months)?
- AbbVie (ABBV) reported aoci - cash flow hedge reclassification (next 12 months) of -$36.00M in Q3 2025.
- What does aoci - cash flow hedge reclassification (next 12 months) mean?
- The amount of hedge gains or losses expected to hit the income statement over the next 12 months.